Search review questions

Parenting stress; postintervention · parents of children between the ages of 0 and 18 years

Parent mindfulness; postintervention · parents of children between the ages of 0 and 18 years

Measures of self‐compassion · parents of children between the ages of 0 and 18 years

Child emotional and behavioural adjustment; postintervention · parents of children between the ages of 0 and 18 years

Adverse effects · parents of children between the ages of 0 and 18 years

All‐cause mortality · participants with gallstone disease (cholesterol, pigment, or mixed)

Serious adverse events at longest · participants with gallstone disease (cholesterol, pigment, or mixed)

Health‐related quality of life · participants with gallstone disease (cholesterol, pigment, or mixed)

Clinical relapse (at 30‐32 weeks, CDAI > 150) · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)

Loss of clinical response · Crohn's disease patients (in remission at baseline)

Withdrawal due to adverse events · Crohn's disease patients (in remission at baseline)

Serious adverse events (at 2 years) · Crohn's disease patients (in remission at baseline)

Clinical relapse (at 52 weeks, HBI > 4) · patients with Crohn's disease (with mixed/low disease activity at baseline)

Loss of clinical response (at 52 weeks, HBI change from baseline of less than 4 points and a total score of less than 7 points) · patients with Crohn's disease (with mixed/low disease activity at baseline)

Withdrawal due to adverse events (at 52 weeks) · patients with Crohn's disease (with mixed/low disease activity at baseline)

Serious adverse events (at 52 weeks) · patients with Crohn's disease (with mixed/low disease activity at baseline)

Clinical relapse (at 22 weeks, CDAI > 150) · patients with Crohn's disease (active disease population with clinical response at baseline)

Loss of clinical response (at 22 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (active disease population with clinical response at baseline)

Withdrawal due to adverse events (at 30 weeks) · patients with Crohn's disease (active disease population with clinical response at baseline)

Loss of clinical response (at 32 weeks, less than 70 points in CDAI change) · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)

Serious adverse events · patients with Crohn's disease (active disease population with clinical response at baseline)

Clinical relapse · patients with Crohn's disease (active disease population with clinical response at baseline)

Loss of clinical response (at 56 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (active disease population with clinical response at baseline)

Withdrawal due to adverse events (at 56 weeks) · patients with Crohn's disease (active disease population with clinical response at baseline)

Serious adverse events (at 56 weeks) · patients with Crohn's disease (active disease population with clinical response at baseline)

Withdrawal due to adverse events (at 32‐54 weeks) · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)

Serious adverse events (at 54 weeks) · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)

Clinical relapse (at 48 weeks, CDAI of 150 or greater together with an increase in CDAImore than 70 points above baseline over 2 consecutive weeks or definitive clinical relapse requiring immediate intervention, as judged by the treating physician) · Crohn's disease patients (in remission at baseline)

Loss of clinical response · Crohn's disease patients (in remission at baseline)

Withdrawal due to adverse events (at 48 weeks) · Crohn's disease patients (in remission at baseline)

Serious adverse events (at 48 weeks to 2 years) · Crohn's disease patients (in remission at baseline)

Clinical relapse · Crohn's disease patients (in remission at baseline)

Live birth or ongoing pregnancy · women undergoing IVF/ICSI

IU vs 150 IU · women undergoing IVF/ICSI who are anticipated to have a normal response to stimulation based on at least one ORT measure

IU vs 100 IU · women undergoing IVF/ICSI who are anticipated to have a hyper‐response to stimulation based on at least one ORT measure

OHSS · women undergoing IVF/ICSI

Clinical pregnancy · women undergoing IVF/ICSI

300/450 IU vs 150 IU · women undergoing IVF/ICSI who are anticipated to have a low response to stimulation based on one or more ORT measure

400/450 IU vs 300 IU · women undergoing IVF/ICSI who are anticipated to have a low response to stimulation based on one or more ORT measure

IU vs 450 IU · women undergoing IVF/ICSI who are anticipated to have a low response to stimulation based on one or more ORT measure

IU vs 100 IU · women undergoing IVF/ICSI who are anticipated to have a normal response to stimulation based on at least one ORT measure

225/200 IU vs 150 IU · women undergoing IVF/ICSI who are anticipated to have a normal response to stimulation based on at least one ORT measure

IU vs 225 IU · women undergoing IVF/ICSI who are anticipated to have a normal response to stimulation based on at least one ORT measure

Mortality before hospital discharge · preterm infants with respiratory distress

Death or chronic lung disease · newborn (term* and preterm) infants with respiratory distress for initial respiratory support

Intraventricular haemorrhage, Papile grade 3/4 · newborn (term* and preterm) infants with respiratory distress for initial respiratory support

Neurodevelopmental disability · newborn (term* and preterm) infants with respiratory distress for initial respiratory support

Mortality before hospital discharge · preterm infants with respiratory distress for initial respiratory support

Endotracheal intubation To discharge · preterm infants with respiratory distress for initial respiratory support

Chronic lung disease · preterm infants with respiratory distress for initial respiratory support